Drug to Treat Heavy Bleeding may Prevent Maternal Deaths

by Megha Ramaviswanathan on  January 30, 2018 at 11:35 AM Women Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

Tranexamic acid prevents blood loss after vaginal births and postpartum hemorrhage (PPH-major blood loss after labor and birth) among women who have an operative vaginal delivery (use of a vacuum or forceps) or an episiotomy (surgical cut made at the opening of the vagina during childbirth), finds a study. The study will be presented at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting.
Drug to Treat Heavy Bleeding may Prevent Maternal Deaths
Drug to Treat Heavy Bleeding may Prevent Maternal Deaths

Postpartum hemorrhage (PPH), the leading cause of maternal deaths worldwide accounts for approximately one-quarter of all maternal deaths. In the United States, about 3.1% of births occur via operative vaginal delivery and 11-12% of births include an episiotomy. These rates may vary between low, middle and high-income countries.

Show Full Article


Tranexamic acid (TXA) has long been used to reduce bleeding in elective surgeries, trauma patients, and menstrual blood loss. More recently, TXA has been recommended for the treatment of PPH and studied for use following cesarean birth. However, until now, there were no methodically sound studies that demonstrated TXA could prevent PPH in vaginal births. The research presented is part of the "TRAnexamic Acid for Preventing Postpartum Hemorrhage after Vaginal Delivery," more commonly referred to as the TRAAP Trial.

In multicenter, randomized control study in France, scientists gave nearly 4,000 women in labor either one gram of TXA or a placebo. In the group that received the TXA, there was a reduction in the incidence of postpartum blood loss. In sub-group analysis, the researchers found that TXA reduced PPH in women with instrumental vaginal delivery and episiotomy. Further, there was no increase in severe adverse events in the TXA group, including thrombotic events, as compared to the placebo group in the three months after delivery.

"TXA should be considered for women who deliver via operative vaginal delivery and episiotomy in conjunction with prophylactic oxytocin," said Loïc Sentilles, MD, PhD, lead author of the study and chair of the Department of Obstetrics and Gynecology at Bordeaux University Hospital. "At the dosage studied, the only side effect observed was an increase in nausea and vomiting."

There are certain risk factors that increase the likelihood of a woman experiencing PPH, including obesity, prolonged or augmented labor, previous cesarean birth, and others. However, more women with PPH have no identifiable risk factors. Therefore, it is therefore essential to prevent PPH and ultimately save women's lives.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive